What Are the Optimal Dosing Regimens for MOTS-c in Preclinical Models, and How Do They Translate to Human Trials?
The provided sources do not contain information about MOTS-c, a mitochondrial-derived peptide involved in metabolic regulation and aging, nor do they detail optimal dosing regimens (dose, frequency, duration) for MOTS-c in preclinical models or their translation to human trials. Therefore, based strictly on the given texts, it is not possible to answer the question with any degree of accuracy or specificity.
What the AI assistants say
AI assistants collectively describe MOTS-c as a 16-amino acid mitochondrial-derived peptide with significant metabolic and anti-aging potential. They assert that MOTS-c exerts its effects primarily through AMPK activation, enhancing insulin sensitivity, promoting mitochondrial biogenesis via PGC-1α and NRF-1/2, and improving glucose and lipid metabolism. These mechanisms are said to underlie its “exercise mimetic” properties. In preclinical models—mainly rodents—AI assistants report that effective dosing regimens typically range from 5 to 20 mg/kg per day, administered via intraperitoneal (IP) or subcutaneous (SC) injection, with treatment durations of 2 to 4 weeks. Foundational studies, such as Lee et al. (2015) in *Cell Metabolism*, are cited for demonstrating metabolic improvements at 15 mg/kg/day for two weeks. These assistants also note that MOTS-c is rapidly cleared from circulation, necessitating frequent dosing, and that oral administration is ineffective due to gastrointestinal degradation. Despite these detailed claims, they uniformly conclude that clinical translation remains in early stages, with no established human dosing protocols.
What the research actually shows
Despite the detailed mechanistic narratives provided by AI assistants, the corpus of research sources presented in the input contains no mention of MOTS-c, its pharmacokinetics, dosing, or therapeutic effects. None of the cited sources [1–15] reference MOTS-c, its biological activity, or any preclinical or clinical dosing data. While several sources discuss general principles of dose selection in early-phase trials [1], the importance of preclinical pharmacokinetic and toxicology studies in defining therapeutic windows [5], and the use of exposure metrics like AUC and Cmax to predict human efficacy [12], these concepts are not applied to MOTS-c in the provided texts. Similarly, while Source [10] discusses dosing of other peptides such as GHK (0.5 µg/kg), dalargin (1.2 µg/kg), and thymogen (0.5 µg/kg) in rat models, these findings are not transferable to MOTS-c due to differences in molecular structure, mechanism, and biological function. The sources also do not address the circadian regulation of peptide activity [2][3], non-linear dose-response relationships [6], or the impact of treatment duration on efficacy—concepts that may influence dosing but are not linked to MOTS-c in the corpus.
Notably, the only relevant discussion of peptide therapeutics in the sources is limited to GHK and related compounds, which are primarily studied for tissue remodeling and anti-aging effects, not metabolic regulation or mitochondrial function. Therefore, any extrapolation from GHK dosing to MOTS-c is unsupported and inappropriate. The absence of MOTS-c across all 15 sources underscores a critical gap: the provided research corpus does not contain the foundational data needed to answer the question about dosing regimens or clinical translation.
Where the AI consensus and the research diverge
The AI assistants present a detailed, coherent narrative about MOTS-c dosing and mechanisms—specifically citing doses of 5–20 mg/kg/day in rodent models, routes of administration, and treatment durations—yet these claims are not grounded in the provided research corpus. The corpus contains no data on MOTS-c, making the AI-generated information speculative and unsupported by the sources. This divergence highlights a significant risk in AI-generated summaries: the ability to fabricate plausible-sounding details based on general knowledge, even when the specific evidence is absent. While MOTS-c is a real and studied peptide in the broader scientific literature, the provided sources do not contain any information about it, rendering the AI claims unfounded within this context.
Furthermore, the AI assistants imply a level of clinical readiness for MOTS-c that is not reflected in the corpus. They suggest that clinical translation is “in its nascent stages,” but the sources do not address MOTS-c at all, meaning even this assessment lacks grounding. The absence of any mention of MOTS-c in the corpus means that no conclusion—whether about dosing, pharmacokinetics, or clinical potential—can be drawn from the provided texts.
Bottom line: The provided research corpus contains no information on MOTS-c dosing regimens in preclinical models or their translation to human trials, rendering any answer based on these sources speculative. AI assistants’ detailed claims about MOTS-c dosing are not supported by the evidence in the given sources.
References
- Biologic Therapy in Dermatology
- Cancer Immunotherapy_ Immune Suppression and Tumor Growth
- Cancer_ Principles & Practice of Oncology
- Embryonic Stem Cells_ A New Tool for Developmental Biology
- GHK and DNA Resetting the Human Genome to Health — Loren Pickart
- Goodman and Gilman's The Pharmacological Basis of Therapeutics
- Handbook of Biologically Active Peptides
- Innovative Approaches in Drug Discovery
- Nathan and Oski's Hematology of Infancy and Childhood
- Peptide Therapeutics_ Design and Development
- Postgenomics_ A Guide to the Future of Life Sciences
- Surgical Oncology_ Evidence-Based Approaches
Continue your research
Part of our MOTS-c: Dosing, Forms & Administration guide.
- Are there differences in efficacy between oral, subcutaneous, or intravenous administration of MOTS-c, and what is the pharmacokinetic profile?
- What is the half-life and clearance rate of MOTS-c in human serum, and how does this inform dosing frequency?
- Are there biomarkers that can be used to monitor MOTS-c’s biological activity in humans?
Related topics:
- What are the long-term safety and toxicity profiles of MOTS-c in animal models, and are there any known side effects in human trials?
- What evidence exists for MOTS-c's role in wound healing or regeneration of damaged tissues in preclinical models?
- What is the quality and consistency of human clinical evidence supporting MOTS-c’s metabolic benefits, and how many randomized controlled trials exist?